FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2111031611> ?p ?o ?g. }

• W2111031611 endingPage "714" @default.
• W2111031611 startingPage "709" @default.
• W2111031611 abstract "In this trial, stopping bevacizumab after completion of induction chemotherapy was associated with a shorter time to progression, but no statistically significant difference in overall survival compared with the bevacizumab continuation strategy. Non-inferiority could not be demonstrated. Treatment costs are substantially higher for continuous bevacizumab treatment.BackgroundChemotherapy plus bevacizumab is a standard option for first-line treatment in metastatic colorectal cancer (mCRC) patients. We assessed whether no continuation is non-inferior to continuation of bevacizumab after completing first-line chemotherapy.Patients and methodsIn an open-label, phase III multicentre trial, patients with mCRC without disease progression after 4–6 months of standard first-line chemotherapy plus bevacizumab were randomly assigned to continuing bevacizumab at a standard dose or no treatment. CT scans were done every 6 weeks until disease progression. The primary end point was time to progression (TTP). A non-inferiority limit for hazard ratio (HR) of 0.727 was chosen to detect a difference in TTP of 6 weeks or less, with a one-sided significance level of 10% and a statistical power of 85%.ResultsThe intention-to-treat population comprised 262 patients: median follow-up was 36.7 months. The median TTP was 4.1 [95% confidence interval (CI) 3.1–5.4] months for bevacizumab continuation versus 2.9 (95% CI 2.8–3.8) months for no continuation; HR 0.74 (95% CI 0.58–0.96). Non-inferiority could not be demonstrated. The median overall survival was 25.4 months for bevacizumab continuation versus 23.8 months (HR 0.83; 95% CI 0.63–1.1;P = 0.2) for no continuation. Severe adverse events were uncommon in the bevacizumab continuation arm. Costs for bevacizumab continuation were estimated to be ∼30 000 USD per patient.ConclusionsNon-inferiority could not be demonstrated for treatment holidays versus continuing bevacizumab monotheray, after 4–6 months of standard first-line chemotherapy plus bevacizumab. Based on no impact on overall survival and increased treatment costs, bevacizumab as a single agent is of no meaningful therapeutic value. More efficient treatment approaches are needed to maintain control of stabilized disease following induction therapy.Clinical trial registrationClinicalTrials.gov, number NCT00544700." @default.
• W2111031611 created "2016-06-24" @default.
• W2111031611 creator A5001536238 @default.
• W2111031611 creator A5003575711 @default.
• W2111031611 creator A5008912538 @default.
• W2111031611 creator A5010203773 @default.
• W2111031611 creator A5012174779 @default.
• W2111031611 creator A5012453950 @default.
• W2111031611 creator A5025804381 @default.
• W2111031611 creator A5035736007 @default.
• W2111031611 creator A5039236556 @default.
• W2111031611 creator A5043294492 @default.
• W2111031611 creator A5051345950 @default.
• W2111031611 creator A5054034732 @default.
• W2111031611 creator A5060531617 @default.
• W2111031611 creator A5062212180 @default.
• W2111031611 creator A5065813790 @default.
• W2111031611 creator A5069753402 @default.
• W2111031611 creator A5070477073 @default.
• W2111031611 creator A5075265048 @default.
• W2111031611 creator A5087142746 @default.
• W2111031611 creator A5090015527 @default.
• W2111031611 date "2015-04-01" @default.
• W2111031611 modified "2023-10-18" @default.
• W2111031611 title "Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06)" @default.
• W2111031611 cites W1803187083 @default.
• W2111031611 cites W1973794297 @default.
• W2111031611 cites W2095913691 @default.
• W2111031611 cites W2096651590 @default.
• W2111031611 cites W2122152991 @default.
• W2111031611 cites W2124451268 @default.
• W2111031611 cites W2125447919 @default.
• W2111031611 cites W2127941773 @default.
• W2111031611 cites W2143743735 @default.
• W2111031611 cites W2144690940 @default.
• W2111031611 cites W2157769714 @default.
• W2111031611 cites W2160373161 @default.
• W2111031611 cites W2161664263 @default.
• W2111031611 cites W2165906785 @default.
• W2111031611 cites W2241411979 @default.
• W2111031611 doi "https://doi.org/10.1093/annonc/mdv011" @default.
• W2111031611 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25605741" @default.
• W2111031611 hasPublicationYear "2015" @default.
• W2111031611 type Work @default.
• W2111031611 sameAs 2111031611 @default.
• W2111031611 citedByCount "109" @default.
• W2111031611 countsByYear W21110316112014 @default.
• W2111031611 countsByYear W21110316112015 @default.
• W2111031611 countsByYear W21110316112016 @default.
• W2111031611 countsByYear W21110316112017 @default.
• W2111031611 countsByYear W21110316112018 @default.
• W2111031611 countsByYear W21110316112019 @default.
• W2111031611 countsByYear W21110316112020 @default.
• W2111031611 countsByYear W21110316112021 @default.
• W2111031611 countsByYear W21110316112022 @default.
• W2111031611 countsByYear W21110316112023 @default.
• W2111031611 crossrefType "journal-article" @default.
• W2111031611 hasAuthorship W2111031611A5001536238 @default.
• W2111031611 hasAuthorship W2111031611A5003575711 @default.
• W2111031611 hasAuthorship W2111031611A5008912538 @default.
• W2111031611 hasAuthorship W2111031611A5010203773 @default.
• W2111031611 hasAuthorship W2111031611A5012174779 @default.
• W2111031611 hasAuthorship W2111031611A5012453950 @default.
• W2111031611 hasAuthorship W2111031611A5025804381 @default.
• W2111031611 hasAuthorship W2111031611A5035736007 @default.
• W2111031611 hasAuthorship W2111031611A5039236556 @default.
• W2111031611 hasAuthorship W2111031611A5043294492 @default.
• W2111031611 hasAuthorship W2111031611A5051345950 @default.
• W2111031611 hasAuthorship W2111031611A5054034732 @default.
• W2111031611 hasAuthorship W2111031611A5060531617 @default.
• W2111031611 hasAuthorship W2111031611A5062212180 @default.
• W2111031611 hasAuthorship W2111031611A5065813790 @default.
• W2111031611 hasAuthorship W2111031611A5069753402 @default.
• W2111031611 hasAuthorship W2111031611A5070477073 @default.
• W2111031611 hasAuthorship W2111031611A5075265048 @default.
• W2111031611 hasAuthorship W2111031611A5087142746 @default.
• W2111031611 hasAuthorship W2111031611A5090015527 @default.
• W2111031611 hasBestOaLocation W21110316111 @default.
• W2111031611 hasConcept C121608353 @default.
• W2111031611 hasConcept C126322002 @default.
• W2111031611 hasConcept C141071460 @default.
• W2111031611 hasConcept C143998085 @default.
• W2111031611 hasConcept C168563851 @default.
• W2111031611 hasConcept C199360897 @default.
• W2111031611 hasConcept C203092338 @default.
• W2111031611 hasConcept C207103383 @default.
• W2111031611 hasConcept C2776694085 @default.
• W2111031611 hasConcept C2777802072 @default.
• W2111031611 hasConcept C2908647359 @default.
• W2111031611 hasConcept C41008148 @default.
• W2111031611 hasConcept C44249647 @default.
• W2111031611 hasConcept C526805850 @default.
• W2111031611 hasConcept C71924100 @default.
• W2111031611 hasConcept C88626702 @default.
• W2111031611 hasConcept C99454951 @default.
• W2111031611 hasConceptScore W2111031611C121608353 @default.
• W2111031611 hasConceptScore W2111031611C126322002 @default.
• W2111031611 hasConceptScore W2111031611C141071460 @default.

• next